NEDD9 and breast cancer: In conclusion, we demonstrated that inhibition of HDAC4 stimulated NEDD9-FAK signaling pathway, leading to metastasis of breast cancer cell, and consequently limiting the clinical efficacy of pan-HDAC inhibitors against breast cancer (Fig. 6h).